Evidence map›Paper›PMID 36501132›Full record

ArticleNutrients2022

Caffeine, D-glucuronolactone and Taurine Content in Energy Drinks: Exposure and Risk Assessment.

Carmen Rubio, Montaña Cámara, Rosa María Giner, María José González-Muñoz, Esther López-García, Francisco J Morales, M Victoria Moreno-Arribas, María P Portillo, Elena Bethencourt

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Advancement in Nanotablet Research: An Overview.Recent advances in drug delivery and formulation · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Carmen RubioToxicology Department, Pharmacy and Health Sciences Faculties, Universidad de La Laguna (ULL), 38071 San Cristóbal de La Laguna, Spain.ORCID 0000-0001-8774-5870
Montaña CámaraNutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, 28040 Madrid, Spain.ORCID 0000-0001-9232-0703
Rosa María GinerDepartment of Pharmacology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain.ORCID 0000-0001-5455-5923
María José González-MuñozDepartment of Biomedical Sciences, Toxicology Unit, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.ORCID 0000-0003-2383-3788
Esther López-GarcíaDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid, Spain/IdiPAZ, CIBER of Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
Francisco J MoralesInstitute of Food Science, Technology and Nutrition (ICTAN-CSIC), 28040 Madrid, Spain.ORCID 0000-0003-3984-7009
M Victoria Moreno-ArribasInstitute of Food Science Research (CIAL), CSIC-UAM, 28049 Madrid, Spain.ORCID 0000-0002-4136-595X
María P PortilloNutrition and Obesity Group, Department of Pharmacy and Food Sciences, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0003-0210-6549
Elena BethencourtElena Bethencourt Barbuzano, Toxicology Department, Pharmacy and Health Sciences Faculties, Universidad de La Laguna (ULL), 38071 San Cristóbal de La Laguna, Spain.ORCID 0000-0003-2931-7848
Universidad de La Laguna · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto de Ciencia y Tecnología de Alimentos y Nutrición · ESInstituto de Investigación en Ciencias de la Alimentación · ESUniversidad Complutense de Madrid · ESUniversidad de Alcalá · ESUniversitat de València · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consumption of energy drinks (EDs) is increasing globally while the evidence and concern about the potential health risks are also growing. Caffeine (generally 32 mg/100 mL) together with a wide variety of other active components such as taurine (usually 4000 mg/L) and D-glucuronolactone (generally 2400 mg/L) are the main ingredients of EDs. This study aims to assess the exposures to caffeine, taurine and D-glucuronolactone from EDs in various consumption scenarios and consumer profiles and to characterize the risks by evaluating caffeine and taurine intakes with their reference values and by calculating the margin of safety (MOS) for D-glucuronolactone. While the exposure assessment results showed that caffeine intakes from EDs ranged from 80 to 160 mg (1.14-4 mg/kg b.w.) for the considered scenarios, the risk characterization estimated some risks that could be managed with consumption recommendations such as limiting EDs in 40, 60 and 80 kg b.w. consumers to 175, 262.5 and 350 mL, respectively, to prevent sleep disturbances and to 375, 562.5 and 750 mL to prevent general caffeine adverse health risks, respectively. Dietary exposure to D-glucuronolactone from EDs ranged from 600 to 1200 mg (7.5-30 mg/kg b.w.). As D-glucuronolactone MOS ≥ 100 is only observed when EDs consumption is limited to 250 mL, for individuals weighing above 60 kg, some risks were observed in some of the studied scenarios. A taurine exposure from EDs varied from 1000 to 2000 mg (12.5-50 mg/kg b.w.) and consumptions over 500 mL were estimated to generate intakes above the reference value. In conclusion, the management of these risks requires a European legal framework for EDs with maximum limits for the active components, volume size limitations and labeling improvements along with the development of education and awareness programs and risk communication actions in collaboration with the industry and society.

Indexed as

Energy DrinksCaffeineGlucuronatesHumansRisk AssessmentTaurineCaffeineGlucuronatesglucuronolactoneTaurinecaffeineD-glucuronolactoneenergy drinksexposure assessmentrisk characterizationrisk managementtaurine

Identifiers

PMID36501132
PMCPMC9735529
OpenAlexW4311050677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.